The biotechnology company utilizes glycosylated triterpenoids to selectively permeabilize endosomal membranes, allowing for the escape of macromolecule therapeutics from endosomes and enhancing target engagement. This approach improves the therapeutic window and has the potential to re-open drug development pathways for macromolecule therapeutics lacking efficacy and explore new targets considered "undruggable". Sapreme's proprietary endosomal escape platform is available for partnering and can be applied to any biologic modality or indication without limitation.